Get the Stockscreener App
4.00
2.83%
0.11
After Hours:
3.80
-0.20
-5.00%
Corvus Pharmaceuticals Inc stock is traded at $4.00, with a volume of 970.87K.
It is up +2.83% in the last 24 hours and up +5.82% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$3.89
Open:
$3.88
24h Volume:
970.87K
Relative Volume:
0.96
Market Cap:
$347.02M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-7.1429
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
+7.24%
1M Performance:
+5.82%
6M Performance:
-25.23%
1Y Performance:
+119.78%
1-Day Range:
$3.7101
$4.00
1-Week Range:
$3.7101
$4.3763
52-Week Range:
$1.75
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
4.00 | 347.02M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Financial Metrics Exploration: Understanding Corvus Pharmaceuticals Inc (CRVS) Through Ratios - DWinneX
Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk - Seeking Alpha
Corvus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Corvus reports promising interim data on atopic dermatitis drug By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Nasdaq
Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results - MarketScreener
Corvus reports promising interim data on atopic dermatitis drug - Investing.com Australia
Corvus Pharmaceuticals (CRVS) Reports Promising Results for Atopic Dermatitis Treatment | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis - marketscreener.com
Corvus Pharmaceuticals Announces Full Data from Cohort 3 - GlobeNewswire
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN
CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus
Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating By Investing.com - Investing.com India
Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World
Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus
Corvus Pharmaceuticals (CRVS) Sees Notable Increase in Borrow Ra - GuruFocus
Spotlight On Top Penny Stocks For May 2025 - simplywall.st
Corvus Pharmaceuticals’ (CRVS) Outperform Rating Reiterated at Oppenheimer - Defense World
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript - Insider Monkey
Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS S - GuruFocus
Corvus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS Stock News - GuruFocus
Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased - Asianet Newsable
Why Is Corvus Pharmaceuticals Stock Soaring On Friday? - Benzinga
Corvus Pharmaceuticals shares surge on positive trial results By Investing.com - Investing.com Nigeria
Corvus Pharmaceuticals shares surge on positive trial results - Investing.com
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating - marketscreener.com
Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo
Corvus: Q1 Earnings Snapshot - New Haven Register
Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Corvus reports positive phase 1 trial results for atopic dermatitis drug - Investing.com
Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket - marketscreener.com
Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports Promising Q1 2025 Results - TipRanks
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Corvus Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CRVS) - Seeking Alpha
Earnings call transcript: Corvus Pharmaceuticals Q1 2025 sees stock surge despite EPS miss - Investing.com India
Corvus Pharmaceuticals Reports Positive Phase 1 Trial Results - TipRanks
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of - GlobeNewswire
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corvus Pharmaceuticals Inc Stock (CRVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MILLER RICHARD A MD | President and CEO |
May 07 '25 |
Option Exercise |
3.50 |
559,073 |
1,956,756 |
1,136,707 |
0.78%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):